Jeevanrekha- Haryana Model for Treatment and Eliminating Hepatitis C
DOI:
https://doi.org/10.12974/2312-5411.2019.06.5Keywords:
Chronic hepatitis C, Sofosbuvir, Velpatasvir, Daclastavir, Jeevan rekha.Abstract
Introduction: The prevalence of chronic hepatitis C virus (HCV) infection has been estimated at between 1.2% and 1.7% in the adult global population whereas estimated figure in India is around 1% but there are no discrete studies for the same. The high cost and long waitlist in developed countries causes unnecessary delay but situation is totally reverse in Haryana, India where with efforts of government, treatment is free of cost to every resident and that too without any waiting period.
Review of Literature: HCV, a single stranded RNA can go into chronic phase in 85% of patients and rest can clear this virus on its own. The patients who develop Chronic hepatitis C, after a prolonged period of ten to twenty years can develop cirrhosis in 5-20 % of patients. Few years back, the treatment was given with simple Interferon, followed by Pegylated Interferon & Ribavarin for 24 -48 weeks but after availability of Directly acting antiviral agents (DAA'S), interferon free era of treatment has started since December, 2015 in India.
Summary and Conclusions: The main hindrance in treatment of chronic hepatitis C in developed countries is long waiting list and cost of therapy whereas in India, Haryana with help of Jeevan rekha Model, acts of commission has been removed and purchasing is done through open transparent tenders, thus free treatment to every resident has been made available to needy patients for controlling hepatitis C.
References
Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61 (1 suppl): S45-S57. https://doi.org/10.1016/j.jhep.2014.07.027
Ray SC, Thomas DL. Hepatitis C. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th ed. Philadelphia, Pennsylvania: Saunders; 2015: 1904-1927.
Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61(1): 77-87. https://doi.org/10.1002/hep.27259
American Association for the Study of Liver Diseases/ Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. July 6, 2016. Available at: www.hcvguidelines.org. Accessed January 7, 2017.
Harvoni (sofosbuvir/ledipasvir) prescribing information. Forest City, California: Gilead Sciences; February 2017.
Daklinza (daclatasvir) prescribing information. Princeton, New Jersey: Bristol-Myers Squibb; February 2016.
Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type-2 diabetes in chronic hepatitis C. Hepatology 2009; 49(3): 739-744. https://doi.org/10.1002/hep.22703
Hsu YC, Lin JT, Ho HJ. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59(4): 1293-1302. https://doi.org/10.1002/hep.26892